Cancer Breakthrough Lasts Nearly 4 Years!

UroGen just dropped some wild data: their JELMYTO treatment for a rare urinary tract cancer is keeping patients cancer-free for almost four years on average! Even better, it works whether the cancer is new or coming back. This is the first FDA-approved non-surgical option for this cancer, and the results are so strong that analysts are hyped on the stock. Biotech is seriously having a moment, and this could be a game-changer for patients who want to avoid surgery. #CancerBreakthrough #BiotechNews #UroGen #CancerResearch #Oncology #MedicalInnovation #Health